EFFECT OF AGE ON RESPONSE OF SECONDARY HYPERTENSION TO SPECIFIC TREATMENT

被引:59
作者
STREETEN, DHP
ANDERSON, GH
WAGNER, S
机构
[1] The Department of Medicine, State University of New York Health Science Center, Syracuse, Department of Medicine, University Hospital, Syracuse, NY, 13210
关键词
Age-hypertension relationship; Hypercortisolism; Hypertension remediability; Hypothyroidism; Primary aldosteronism; Renovascular hypertension; Secondary hypertension;
D O I
10.1093/ajh/3.5.360
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
There is substantial evidence to show that correction of the causes of secondary forms of hypertension usually but certainly not always restores blood pressure to normal. We have analyzed the effect of age on the response of the blood pressure to the removal of the cause of hypertension in groups of patients with primary aldosteronism, renovascular hypertension, Cushing’s syndrome and hypothyroid hypertension. In the patients studied, surgical or medical elimination of the mechanism responsible for the hypertension when the patients were below the age of 40 reduced diastolic blood pressure 1 to 2 years later to below 90 mm Hg in 24 of 25 patients. In the patients who were treated when they were over 40 years of age, blood pressure remained above 90 mm Hg after corrective treatment in 23 of 61 individuals (38%). In the 4 groups studied there was a significant correlation between age and post-treatment systolic and/or diastolic blood pressure. The findings indicate the importance of correcting secondary hypertension at an early age. © 1990 by the American Journal of Hypertension, Ltd.
引用
收藏
页码:360 / 365
页数:6
相关论文
共 19 条
[1]  
Conn J.W., The evolution of primary aldosteronism, Harvey Lect 1954-1967, 62, pp. 257-291, (1968)
[2]  
Ferriss J.B., Beevers D.G., Boddy K., Et al., The treatment of low-renin (“primary”) hyperaldosteronism, Am Heart J, 96, pp. 97-109, (1978)
[3]  
Manger W.M., Gifford R.W., Pheochromocytoma, (1977)
[4]  
Stanley J.C., Fry W.J., Surgical treatment of renovascular hypertension, Arch Surg, 112, pp. 1291-1297, (1977)
[5]  
Kaufman J.J., Renovascular hypertension: the UCLA experience, J Urol, 121, pp. 139-144, (1979)
[6]  
Streeten D.H.P., Anderson G.H., Hypertension: relating drug therapy to pathogenetic mechanisms, Progress in Drug Research, pp. 176-194, (1988)
[7]  
Vaughan E.d., Buhler F.R., Laragh J.H., Et al., Renovascular hypertension: renin measurements to indicate hypersecretion and contralateral suppression, estimate renal plasma flow, and score for surgical curability, Am J Med, 55, pp. 402-414, (1973)
[8]  
Streeten D.H.P., Anderson G.H., Freiberg J.M., Dalakos T.G., Use of an angiotensin II antagonist (saralasin) in the recognition of “angiotensinogenic” hypertension, New Engl J Med, 292, pp. 657-662, (1975)
[9]  
Streeten D.H.P., Anderson G.H., Outpatient experience with saralasin Kidney Int, 15, pp. S44-S52, (1979)
[10]  
Streeten D.H.P., Anderson G.H., Howland T., Et al., Effects of thyroid function on blood pressure. Recognition of hypothyroid hypertension, Hypertension, 11, pp. 78-83, (1988)